Otsuka Pharmaceutical plans to buy Jnana Therapeutics for $800 million in cash, gaining access to the privately held biotech’s drug discovery platform and an experimental medicine that’s already ...

BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for ...

Otsuka Pharmaceutical has picked up Boston-based Jnana Therapeutics for $800 million so the Japanese biotech can get its hands on a clinical-stage oral phenylketonuria (PKU) drug. Under the terms of ...

Neurocrine Biosciences has teamed up with Jnana Therapeutics to develop drugs that target solute carrier (SLC) metabolite transporters. The collaboration gives Neurocrine a potential source of small ...

– Supports expanded application of chemoproteomic RAPID platform for small-molecule discovery for hard-to-drug targets – BOSTON--(BUSINESS WIRE)--Jnana Therapeutics, a biotechnology company utilizing ...

Roche deepens ties with Jnana with a second licensing deal Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to tap into the Boston-based ...

Roche has entered into a second collaboration and licensing agreement with Jnana Therapeutics for the discovery of small molecule drugs for the treatment of challenging-to-drug cancer, immune-mediated ...

BOSTON--(BUSINESS WIRE)--Jnana Therapeutics today announced a strategic, multi-target collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery of small molecule ...

BOSTON--(BUSINESS WIRE)--Jnana Therapeutics today announced that Joanne Kotz, Ph.D., a company co-founder, has been named Chief Executive Officer. Dr. Kotz has served as Jnana’s president since ...

TOKYO (Reuters) -Japan's Otsuka Pharmaceutical said on Thursday it agreed to pay more than $1 billion to acquire Jnana Therapeutics as it looks to expand its drug pipeline and research base in the ...

– Company co-founder and scientific leader will drive future growth of chemoproteomic product engine and pipeline programs – BOSTON--(BUSINESS WIRE)--Jnana Therapeutics, a biotechnology company ...

Jnana said in a statement that the funding will allow it to take JNT-517 through proof-of-concept testing in PKU, a genetic disorder caused by an inability to break down the amino acid phenylalanine ...